A Phase 1 Randomized, Double Blinded, Placebo-Controlled Single Dose and Repeat Dose Escalation Study to Evaluate Safety and Tolerability and Pharmacokinetic Characteristics of KDR2-2 in Adult Healthy Male and Female Volunteers
Latest Information Update: 07 Nov 2022
At a glance
- Drugs KDR2-2 (Primary)
- Indications Corneal disorders; Corneal neovascularisation
- Focus Adverse reactions
- Sponsors Guangzhou HuiBoRui Biological
- 12 Nov 2020 New trial record